861106-92-5

Basic information

• Product Name: (2-Amino-6-bromo-phenyl)-methanol
• Synonyms: (2-Amino-6-bromo-phenyl)-methanol;Benzenemethanol, 2-amino-6-bromo-
• CAS NO: 861106-92-5
• Molecular Formula: C₇H₈BrNO
• Molecular Weight: 202.04852
• Mol File: 861106-92-5.mol

Chemical Properties

• Boiling Point: 341.4±27.0 °C(Predicted)
• Appearance: /
• Density: 1.660±0.06 g/cm3(Predicted)
• PKA: 13.80±0.10(Predicted)
• CAS DataBase Reference: (2-Amino-6-bromo-phenyl)-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Amino-6-bromo-phenyl)-methanol(861106-92-5)
• EPA Substance Registry System: (2-Amino-6-bromo-phenyl)-methanol(861106-92-5)

Safety Data

• Hazardous Substances Data: 861106-92-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2-Amino-6-bromo-phenyl)-methanol is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activities. Its antimicrobial, antiviral, and antiparasitic properties make it a promising candidate for the development of new drugs to combat infectious diseases.
Used in Organic Compounds Synthesis:
(2-Amino-6-bromo-phenyl)-methanol is used as a building block in the preparation of various heterocyclic compounds. Its versatile properties allow it to be a key component in the creation of complex organic molecules, contributing to the advancement of organic chemistry and the development of new materials and compounds.
Used in Medicinal Chemistry:
(2-Amino-6-bromo-phenyl)-methanol is utilized in medicinal chemistry for its potential to contribute to the development of new drugs and therapies. Its unique structure and properties make it a valuable tool in the design and synthesis of novel pharmaceutical agents, enhancing the discovery and innovation of new treatments for various diseases and conditions.

Upstream product

• 20776-48-1 2-amino-6-chlorobenzoic acid 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 861106-90-3 2-bromo-6-nitrobenzyl acetate 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 58579-54-7 3-bromo-2-(bromomethyl)-1-nitrobenzene 
• 861106-91-4 (2-bromo-6-nitro-phenyl)-methanol 

Downstream Products

• 1347720-73-3 C₂₁H₂₄BrN₃O₅ 
• 1374764-25-6 C₁₈H₁₆BrN₃O₃ 
• 1394358-00-9 5-bromo-2-(3,5-dimethylphenyl)quinoline 
• 1404491-68-4 2-(3,5-dimethylphenyl)-5-(trimethylsilyl)quinoline 
• 1899832-38-2 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2,4-dihydro-1H-3,1-benzoxazin-2-one 
• 1147531-04-1 3-bromo-2-[[tert-butyl(dimethyl)silyl]oxymethyl] aniline 
• 1347721-40-7 C₁₉H₂₀BrN₃O₂ 
• 1160244-38-1 5-bromo-2-phenyl-1,4-dihydro-2H-benzo[d][1,3]oxazine 
• 861106-93-6 5-bromo-2,4-dihydro-1H-3,1-benzoxazin-2-one 

Relevant articles and documents

Metal-Free C-C/C-N/C-C Bond Formation Cascade for the Synthesis of (Trifluoromethyl)sulfonylated Cyclopenta[ b]indolines

A bis(triflyl)ethylation [triflyl = (trifluoromethyl)sulfonyl] inserted into a sequential cyclization cascade resulted in the direct formation of gem-bis(triflyl)ated cyclopenta[b]indolines from anilide-derived allenols and alkenols. This catalyst- and irradiation-free sequence facilitated the efficient preparation of functionalized tricyclic indoline cores bearing two contiguous stereocenters. The formed cyclopenta[b]indolines can be easily transformed into a wide variety of triflylated indolines, including the tetracycle ring system found in polyveoline.

A Convenient Formal [4+2] Heterocylization Route to Bis(triflyl)tetrahydroquinolines

We report the sustainable and efficient synthesis of a new type of quinoline derivatives bearing one or two SO2CF3 groups. The protocol is metal-, catalyst- and irradiation-free, involves the use of readily available and stable precursors, and avoids the formation of side products. Also, the mild conditions of the process allow the tolerance of a wide range of functional groups.

Red phosphorescent compound and organic electroluminescent device using same

The invention discloses a red phosphorescent compound and an organic electroluminescent device using the same. In an organic electroluminescent device comprising an anode, a hole injection layer, a hole transport layer, a light-emitting layer, an electron

HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF

The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF

Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.

5-SUBSTITUTED 2-PHENYLQUINOLINE COMPLEXES MATERIALS FOR LIGHT EMITTING DIODE

Compounds are provided that comprise a ligand having a 5-substituted 2-phenylquinoline. In particular, the 2-phenylquinoline may be substituted with a bulky alkyl at the 5-position. These compounds may be used in organic light emitting devices, in particular as red emitters in the emissive layer of such devices, to provide devices having improved properties.

GERMANIUM-CONTAINING RED EMITTER MATERIALS FOR ORGANIC LIGHT EMITTING DIODE

Organometallic compounds comprising a germanium-containing substituent are provided. The compounds may be used in organic light emitting devices to provide improved device efficiency, line shape and lifetime. In particular, the compounds comprise a phenyl

POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF

At least one active pharmaceutical ingredient is chosen from polycyclic quinazolines of formula V, pharmaceutically acceptable salts thereof, and hydrates of the pharmaceutically acceptable salts. The active pharmaceutical ingredients disclosed may be inhibitors of protein tyrosine kinase inhibitors and/or aurora kinase. The active pharmaceutical ingredients can be used for treating cancers susceptible to treatment with protein tyrosine kinase inhibitors and/or aurora kinase inhibitors.

1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATME

The invention relates to substituted quinazolinone compunds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C or S; m is 1 when Y is C and m is 2 when Y is S; n is 1 or 2; p is from 0 to 3; q is from 1 to 3; Z is -(CRa/sup